Genetic and pharmacological evidence linking CB1R signaling to hippocampal GABAergic dysfunction in ASD mouse model
4 affiliations
- 1Department of Children’s and Adolescent Health, School of Public Health, Harbin Medical University, Harbin, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, China
- 2Department of Children’s and Adolescent Health, School of Public Health, Harbin Medical University, Harbin, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, China; Yunnan Institute of Endemic Diseases Control and Prevention (YIEDC), Kunming, China
- 3Department of Children’s and Adolescent Health, School of Public Health, Harbin Medical University, Harbin, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, China; Department of Developmental Behavioral Pediatrics, the Sixth Affiliated Hospital of Harbin Medical University, Harbin, China; Corresponding author.
- 4Department of Children’s and Adolescent Health, School of Public Health, Harbin Medical University, Harbin, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, China; Corresponding author.
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder increasingly linked to disrupted GABAergic inhibition and altered excitatory-inhibitory balance. Cannabinoid receptor 1 (CB1R), enriched on GABAergic interneurons, modulates inhibitory tone. Whether CB1R dysfunction in GABAergic neurons contributes to ASD-like phenotypes remains unclear. This study investigated the role of CB1R in GABAergic regulation and evaluated whether pharmacological CB1R activation could ameliorate GABAergic abnormalities and behavioral deficits in ASD models. We generated conditional CB1R knockout mice in GABAergic neurons (GABA-CB1 −/− ) and performed behavioral and molecular ultrastructural analyses. GABAergic and neuronal alterations were quantified in hippocampus and striatum by Western blotting, immunofluorescence, and transmission electron microscopy. SA-PEG-DSPE nanomicelles were used to deliver the CB1R agonist ACPA or in combination with the GABAA receptor agonist muscimol to valproic-acid (VPA)-exposed mice to assess pharmacological modulation. GABA-CB1 −/− mice exhibited social deficits, spatial learning and memory impairments, and repetitive behaviors similar to those of VPA mice. Both models showed increased GAD67 and GABARAP, reduced ABAT, a lower PSD95/gephyrin ratio, a reduced proportion of GAD67+NeuN + neurons, marked dendritic and synaptic disruption in the hippocampus, whereas changes in the striatum were limited. Nanomicelle-mediated ACPA administration ameliorated GABAergic molecular alterations, improved dendritic integrity and ASD-like behaviors, whereas, muscimol co-administration partially attenuated these effects in VPA mice. CB1R deficiency in GABAergic neurons was associated with ASD-like phenotypes accompanied by hippocampal GABAergic dysfunction. Pharmacological CB1R activation ameliorated behavioral and molecular abnormalities, while modulation of GABAAR partially attenuated these effects. These findings support further investigation of CB1R as a potential therapeutic target for ASD.
Related
- Elevated prenatal IL-6 levels disrupt early patterns of hippocampal electrical activity and chloride homeostasis by targeting GABAergic signaling at perinatal stage
- Sedative Potential of L (+)-Tartaric Acid: Behavioral Evidence With In Silico Insights Into Possible GABAergic Interaction.
- Excitatory neuronal TIA1 in ventral hippocampal CA1 drives antidepressant-like effects via downregulation of Cacna2d1 signaling in mice
- Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment
- Pharmacological melatonin induces mitochondrial dysfunction and alters extracellular nucleotide metabolism and CD39/CD73 expression in human melanoma cells.
BibTeX
@article{hu2026genetic,
title = {{Genetic and pharmacological evidence linking CB1R signaling to hippocampal GABAergic dysfunction in ASD mouse model}},
author = {Jingyi Hu and Haoran Wang and Junyu Ren and Tianyu Liu and Yi Jiang and Yilin Zhang and Yuting Zhang and Han Zhang and Caihong Sun and Mingyang Zou},
journal = {Neurotherapeutics},
year = {2026},
month = oct,
doi = {10.1016/j.neurot.2026.e01067},
url = {https://doi.org/10.1016/j.neurot.2026.e01067},
note = {CC BY},
}
RIS
TY - JOUR
TI - Genetic and pharmacological evidence linking CB1R signaling to hippocampal GABAergic dysfunction in ASD mouse model
AU - Jingyi Hu
AU - Haoran Wang
AU - Junyu Ren
AU - Tianyu Liu
AU - Yi Jiang
AU - Yilin Zhang
AU - Yuting Zhang
AU - Han Zhang
AU - Caihong Sun
AU - Mingyang Zou
PY - 2026
DA - 2026/10/24
JO - Neurotherapeutics
DO - 10.1016/j.neurot.2026.e01067
UR - https://doi.org/10.1016/j.neurot.2026.e01067
AB - Autism spectrum disorder (ASD) is a neurodevelopmental disorder increasingly linked to disrupted GABAergic inhibition and altered excitatory-inhibitory balance. Cannabinoid receptor 1 (CB1R), enriched on GABAergic interneurons, modulates inhibitory tone. Whether CB1R dysfunction in GABAergic neurons contributes to ASD-like phenotypes remains unclear. This study investigated the role of CB1R in GABAergic regulation and evaluated whether pharmacological CB1R activation could ameliorate GABAergic abnormalities and behavioral deficits in ASD models. We generated conditional CB1R knockout mice in GABAergic neurons (GABA-CB1 −/− ) and performed behavioral and molecular ultrastructural analyses. GABAergic and neuronal alterations were quantified in hippocampus and striatum by Western blotting, immunofluorescence, and transmission electron microscopy. SA-PEG-DSPE nanomicelles were used to deliver the CB1R agonist ACPA or in combination with the GABAA receptor agonist muscimol to valproic-acid (VPA)-exposed mice to assess pharmacological modulation. GABA-CB1 −/− mice exhibited social deficits, spatial learning and memory impairments, and repetitive behaviors similar to those of VPA mice. Both models showed increased GAD67 and GABARAP, reduced ABAT, a lower PSD95/gephyrin ratio, a reduced proportion of GAD67+NeuN + neurons, marked dendritic and synaptic disruption in the hippocampus, whereas changes in the striatum were limited. Nanomicelle-mediated ACPA administration ameliorated GABAergic molecular alterations, improved dendritic integrity and ASD-like behaviors, whereas, muscimol co-administration partially attenuated these effects in VPA mice. CB1R deficiency in GABAergic neurons was associated with ASD-like phenotypes accompanied by hippocampal GABAergic dysfunction. Pharmacological CB1R activation ameliorated behavioral and molecular abnormalities, while modulation of GABAAR partially attenuated these effects. These findings support further investigation of CB1R as a potential therapeutic target for ASD.
SN - 1878-7479
SN - 1933-7213
ER -